408 related articles for article (PubMed ID: 24002931)
1. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
Flecken T; Schmidt N; Hild S; Gostick E; Drognitz O; Zeiser R; Schemmer P; Bruns H; Eiermann T; Price DA; Blum HE; Neumann-Haefelin C; Thimme R
Hepatology; 2014 Apr; 59(4):1415-26. PubMed ID: 24002931
[TBL] [Abstract][Full Text] [Related]
2. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
Zang C; Zhao Y; Qin L; Liu G; Sun J; Li K; Zhao Y; Sheng S; Zhang H; He N; Zhao P; Wang Q; Li X; Peng Y; Dong T; Zhang Y
BMC Cancer; 2021 Sep; 21(1):1007. PubMed ID: 34496797
[TBL] [Abstract][Full Text] [Related]
3. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
4. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.
Liu Y; Daley S; Evdokimova VN; Zdobinski DD; Potter DM; Butterfield LH
J Immunol; 2006 Jul; 177(1):712-21. PubMed ID: 16785570
[TBL] [Abstract][Full Text] [Related]
5. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.
Hiroishi K; Eguchi J; Baba T; Shimazaki T; Ishii S; Hiraide A; Sakaki M; Doi H; Uozumi S; Omori R; Matsumura T; Yanagawa T; Ito T; Imawari M
J Gastroenterol; 2010 Apr; 45(4):451-8. PubMed ID: 19936602
[TBL] [Abstract][Full Text] [Related]
6. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
Thimme R; Neagu M; Boettler T; Neumann-Haefelin C; Kersting N; Geissler M; Makowiec F; Obermaier R; Hopt UT; Blum HE; Spangenberg HC
Hepatology; 2008 Dec; 48(6):1821-33. PubMed ID: 19003875
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
[TBL] [Abstract][Full Text] [Related]
9. Lack of ex vivo peripheral and intrahepatic α-fetoprotein-specific CD4+ responses in hepatocellular carcinoma.
Witkowski M; Spangenberg HC; Neumann-Haefelin C; Büttner N; Breous E; Kersting N; Drognitz O; Hopt UT; Blum HE; Semmo N; Thimme R
Int J Cancer; 2011 Nov; 129(9):2171-82. PubMed ID: 21170957
[TBL] [Abstract][Full Text] [Related]
10. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
Bricard G; Bouzourene H; Martinet O; Rimoldi D; Halkic N; Gillet M; Chaubert P; Macdonald HR; Romero P; Cerottini JC; Speiser DE
J Immunol; 2005 Feb; 174(3):1709-16. PubMed ID: 15661935
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
13. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
14. [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].
Qiao H; Qian XP; Zhang HG; Tian C; Chen WF
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):565-8. PubMed ID: 16378102
[TBL] [Abstract][Full Text] [Related]
15. Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma.
Tauber C; Schultheiss M; Luca R; Buettner N; Llewellyn-Lacey S; Emmerich F; Zehe S; Price DA; Neumann-Haefelin C; Schmitt-Graeff A; Hofmann M; Thimme R
Oncotarget; 2019 Aug; 10(50):5194-5206. PubMed ID: 31497249
[No Abstract] [Full Text] [Related]
16. Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma.
Zerbini A; Pilli M; Soliani P; Ziegler S; Pelosi G; Orlandini A; Cavallo C; Uggeri J; Scandroglio R; Crafa P; Spagnoli GC; Ferrari C; Missale G
J Hepatol; 2004 Jan; 40(1):102-9. PubMed ID: 14672620
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated antigen specific CD8
Schmidt N; Flecken T; Thimme R
Oncoimmunology; 2014 Oct; 3(9):e954919. PubMed ID: 25941604
[TBL] [Abstract][Full Text] [Related]
19. Specific CD8(+ )T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination.
Zhang HG; Chen HS; Peng JR; Shang XY; Zhang J; Xing Q; Pang XW; Qin LL; Fei R; Mei MH; Leng XS; Chen WF
Cancer Immunol Immunother; 2007 Dec; 56(12):1945-54. PubMed ID: 17522859
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
